SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients

Not Applicable

Completed

• Conditions: Fluid and Electrolyte Imbalance; ADH Inappropriate; Intravenous Fluids

• Registration Number: NCT03924674
• Lead Sponsor: Seattle Children's Hospital

Brief Summary

Intravenous fluids (IVF) are used in hospitalized patients to replenish the fluid and electrolyte losses of patients who cannot take adequate hydration by mouth or through their gut. Inappropriate use of IVF may cause serious problems, including abnormalities in blood electrolytes such as sodium, which can lead to serious but rare neurologic harm; pain and discomfort from multiple IV insertions and subsequent complications (e.g., IV infiltration); and inadequate monitoring for adverse effects.

Investigators currently don't know what the most commonly used IVF in hospitalized pediatric patients are, and there are no national benchmark data for IVF use. The American Academy of Pediatrics published a Guideline on maintenance IVF in November 2018, which contains one major recommendation: to use isotonic (having a similar electrolyte concentration to blood plasma) maintenance IVF in medical and surgical patients 28 days to 18 years old without pre-existing serious illnesses.

This project aims to better describe and standardize the use of IVF in inpatient pediatric settings across the U.S. and evaluate the impact of an intervention bundle on maintenance IVF use. This project aims to improve health care value by reducing the number of routine laboratory draws.

In Quality Improvement research, there are three different types of measures - outcome measures, process measures and balancing measures.

In this project, the following will be used as a process measure:

The proportion of daily weight measurements for patients on maintenance IVF.

The following will be used as balancing measures:

1. There will be no increase in the number of floor-to-PICU transfers during hospitalization from baseline.

2. There will be no increase in the number of serum sodium lab results obtained from baseline.

3. There will be no increase in adverse events prompting a change in clinical management from baseline: hypertension or edema requiring a diuretic, hypertension requiring anti-hypertensive medication, and acute kidney injury (AKI) requiring renal replacement therapy (RRT)/dialysis.

Detailed Description

Study Design

All sites will participate in a stepped wedge cluster randomized trial, with 80-120 sites total. This design is helpful when simultaneous implementation of an intervention is not feasible or practical, and allows for each site to collect baseline data for comparison with post-intervention data. There will be 3 groups (or clusters) of approximately 30-40 sites each, with randomization to intervention occurring at 2 month intervals. Randomization will be stratified by: geographic region, size and baseline rate of IVF use.

Study Timeline

• Study Start: 2019-04-01
• Study First Submitted: 2019-04-06
• Study First Submitted QC: 2019-04-19
• Study First Posted: 2019-04-23
• Primary Completion: 2020-05-31
• Study Completion: 2020-05-31
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-27
• Last Update Posted: 2021-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

• Age ≥28 days and ≤18 years old at the time of admission
• Received maintenance IVF (rate greater than 10 ml/h) on hospital day #2 at 12:01 am

Exclusion Criteria

• ICU (PICU, NICU, CICU, etc.) patients
• Patients who have never gone home from the hospital
• Patients with active adrenal, cardiac, hepatic, neurosurgical, chronic renal, heme/onc, biochemical genetic/metabolic illnesses* (*As evidenced by: (1) listing of a condition in these categories in past medical history; and/or (2) active medication related to one of these conditions)
• Patients with diabetes insipidus, DKA, severe burns
• Patients on a psychiatric hold/primary behavioral health reason for admission with no needed medical management
• Patients with voluminous watery diarrhea > 7 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Fluid Tonicity	Monthly reports will be generated each month for each participating site through study completion, approximately 9 months.	Increase mean proportion of hours per hospital day with exclusive isotonic IVF use to ≥80% by May 2020.
Routine Labs	Monthly reports will be generated each month for each participating site through study completion, approximately 9 months.	Decrease number of serum WBC levels (proxy for routine labs) per hospital day by 20% from baseline by May 2020.

Secondary Outcome Measures

Name	Time	Method
IVF duration	Monthly reports will be generated each month for each participating site through study completion, approximately 9 months.	Decrease proportion of time (hours) on maintenance IVF during hospitalization by 10% from baseline by May 2020.

Trial Locations

Locations (89)

Phoenix Children's Hospital; 🇺🇸 Phoenix, Arizona, United States

Community Regional Medical Center; 🇺🇸 Fresno, California, United States

Loma Linda University Children's Hospital; 🇺🇸 Loma Linda, California, United States

Harbor - UCLA Medical Center; 🇺🇸 Los Angeles, California, United States

UCLA Mattel Children's Hospital; 🇺🇸 Los Angeles, California, United States

Valley Children's Hospital; 🇺🇸 Madera, California, United States

Stanford HealthCare-ValleyCare; 🇺🇸 Pleasanton, California, United States

UCSF Benioff Children's Hospital; 🇺🇸 San Francisco, California, United States

Valley Presbyterian Hospital; 🇺🇸 Van Nuys, California, United States

John Muir Medical Center; 🇺🇸 Walnut Creek, California, United States

Scroll for more (79 remaining)